A start-up named DenovAI, founded by a former EMBL staff scientist, is pioneering a revolutionary approach to expedite and reduce costs in antibody discovery.
At times, advancements in science involve the revelation of entirely novel discoveries, while on other occasions, progress is achieved by enhancing efficiency, speed, or simplicity.